Guide for BRCA testing in prostate cancer

LYNPARZA (olaparib) is indicated as monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer and BRCA1- and/or BRCA2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.^{1,2}

> Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to AstraZeneca on 0800 783 0033 and via contactazmedical@astrazeneca.com.

For a full list of adverse events (AEs), please refer to the SmPCs here. Click on the following links to view the Prescribing Information (GB) or Prescribing Information (NI) for LYNPARZA® (olaparib): Great Britain; Northern Ireland.

BRCA mutations are reported in approximately 1 in 10 patients with prostate cancer³⁻⁷ and can cause increased sensitivity to PARP inhibition⁸

Mutations in BRCA genes can be:⁴



• Of all BRCA mutations in prostate cancer, approximately half are germline and half are somatic⁴



 Prostate cancer driven by BRCA mutations is associated with aggressive disease^{6,7}

What are BRCA1 and **BRCA2** genes?

Both genes encode proteins involved in repairing DNA double-strand breaks via the homologous recombination pathway^{8,11}

LYNPARZA MoA

- BRCA mutations can result in homologous recombination deficiency,^{8,12} and such defects in cells can make them highly sensitive to PARP inhibitors, such as LYNPARZA⁸
- LYNPARZA is indicated as monotherapy for patients with **metastatic castration-resistant prostate** cancer (mCRPC) and BRCA1- and/or BRCA2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent¹

Why should I test my patients for BRCA mutations?




To inform prognosis^{6,7}



To assess familial risk^{14,15}




To determine eligibility for clinical trials^{3,5}





To determine eligibility for treatment with LYNPARZA monotherapy*1

*Patients must have a somatic and/or germline BRCA1 and/or BRCA2 mutation-positive test result to be eligible for treatment with LYNPARZA (privately or in reimbursed countries).¹

How do I test my patients for BRCA mutations?







When and how do I organise a tumour tissue test for my private patient?



- Testing varies depending on location and insurer
- Contact the insurer and explain the potential reason(s) for testing to establish whether they will cover the cost
- Consider contacting your local GLH or designated laboratory service to find out if they offer tumour tissue testing for patients with private healthcare insurance – knowing your patient's NHS number may be helpful
- Tumour tissue testing is also available with independent vendors

Where is my local GLH or designated laboratory service?

Find your local GLH or designated laboratory service



What key steps do I need to be aware of when organising a tumour tissue test?

Use the checklist below:^{32,33}



Contact your local GLH, designated laboratory service or independent vendor to gather all relevant information



Check the reason for BRCA testing and patient eligibility



Check requirements for sample collection and preparation (see local guidance)



Complete the request form provided by your local GLH, designated laboratory service or independent vendor



Label the sample correctly



Send the sample (with any additional documents if needed)







Genomic testing is available for prostate cancer^{‡29}



Tumour tissue testing is a widely available and established method to test for germline and somatic mutations^{15,16}

Testing for **BRCA** mutations may identify patients who are eligible for treatment with LYNPARZA monotherapy^{§1}

For more information on ordering a tumour tissue test and sending patients' samples for testing, contact your local GLH, designated laboratory service or independent vendor

Please check the National Genomic Test Directory for any updates on the availability of these tests in England. Please contact your local designated laboratory service for more information if you are practising in Scotland, Wales or Northern Ireland

[‡]Not currently funded in Scotland and not currently available in Northern Ireland. Subject to change in the future. Information is accurate at the time of infographic development: August 2023; §Privately or in reimbursed countries.

LYNPARZA (olaparib) is also indicated in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated. No testing is required for this indication.^{1,2} LYNPARZA is not reimbursed for this indication in the UK


Information is accurate at the time of infographic development: August 2023.


AE, adverse event; ctDNA, circulating tumour DNA; GLH, genomic laboratory hub; mCRPC, metastatic castration-resistant prostate cancer; MoA, mode of action; NGS, next-generation sequencing; NHS, National Health Service; PARP, poly-ADP ribose polymerase.

References

- LYNPARZA (olaparib). Summary of Product Characteristics. https://www.medicines.org.uk/emc/search?q=Lynparza (accessed August 2023). 1.
- LYNPARZA (olaparib). Summary of Product Characteristics. https://products.mhra.gov.uk/search/?search=Lynparza&page=1&doc=Spc&rerouteType=0 2. (accessed August 2023).
- de Bono J, et al. *N Engl J Med* 2020;382:2091–2102. 3.
- 4. Abida W, et al. JCO Precis Oncol 2017;PO.17.00029.
- Mateo J, et al. *Lancet Oncol* 2020;21:162–174. 5.
- Castro E, et al. Eur Urol 2015;68:186–193. 6.
- Castro E, et al. J Clin Oncol 2013;31:1748-1757. 7.
- Dziadkowiec KN, et al. Prz Menopauzalny 2016;15:215–219. 8.
- National Cancer Institute. Germline mutation. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/germline-mutation (accessed August 2023). 9.
- 10. National Cancer Institute. Somatic mutation. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/somatic-mutation (accessed August 2023). 11. Roy R, et al. *Nat Rev Cancer* 2011;12:68–78.
- 12. O'Connor MJ. Mol Cell 2015;60:547-560.
- 13. Cerrato A, et al. J Exp Clin Cancer Res 2016;35:179.
- 14. Shah S, et al. Int J Mol Sci 2021;22:12628.
- 15. Parker C, et al. Ann Oncol 2020;31:1119–1134.
- 16. Capoluongo E, et al. Semin Oncol 2017;44:187–197.
- 17. Hussain M, et al. Clin Cancer Res 2022;28:1518–1530.
- 18. Ratajska M, et al. Oncotarget 2017;8:101325–101332.
- 19. Cimadamore A, et al. Int J Mol Sci 2021;22:5522.
- 20. Boerrigter E, et al. Expert Rev Mol Diagn 2020;20:219–230.
- 21. Matsubara N, et al. Clin Cancer Res 2023;29:92–99.
- 22. Sydney Cancer Genetics. What is genetic testing? https://www.sydneycancergenetics.com.au/faq/what-is-genetic-testing/ (accessed August 2023).
- 23. NHS England. Genomic laboratory hubs. https://www.england.nhs.uk/genomics/genomic-laboratory-hubs/ (accessed August 2023).
- 24. NHS National Services Scotland. Genetic and molecular pathology laboratories. https://www.nss.nhs.scot/specialist-healthcare/specialist-services/geneticand-molecular-pathology-laboratories/ (accessed August 2023).
- 25. NHS Greater Glasgow and Clyde. Laboratory genetics. https://www.nhsggc.scot/staff-recruitment/staff-resources/laboratory-medicine/laboratory-genetics/ (accessed August 2023).
- 26. NHS Grampian. Clinical genetics service for the North of Scotland. https://www.nhsgrampian.org/service-hub/north-of-scotland-medical-genetics/
- (accessed August 2023). 27. All Wales Medical Genomics Service. Which genetic test do you require? https://medicalgenomicswales.co.uk/index.php/download-services (accessed August 2023).
- 28. Belfast Health and Social Care Trust. Belfast Trust Laboratories user manual. https://belfasttrust.hscni.net/service/laboratory-services/laboratories-usermanual/ (accessed August 2023).
- 29. NHS England. National genomic test directory. https://www.england.nhs.uk/publication/national-genomic-test-directories/ (accessed August 2023). 30. NHS England. Testing criteria for rare and inherited disease. https://www.england.nhs.uk/wp-content/uploads/2018/08/Rare-and-inherited-disease-eligibilitycriteria-version-5.2.pdf (accessed August 2023).
- 31. NHS England. GeNotes. https://www.genomicseducation.hee.nhs.uk/genotes/ (accessed August 2023).
- 32. NHS South West Genomic Laboratory Hub. SWGLH sample and test information. https://www.nbt.nhs.uk/south-west-genomic-laboratory-hub/swglh-sampletest-information (accessed August 2023).
- 33. The Leeds Teaching Hospitals NHS Trust. Molecular oncology diagnostics. https://www.leedsth.nhs.uk/a-z-of-services/the-leeds-genetics-laboratory/ oncology-genetics/molecular-oncology/ (accessed August 2023).
- 34. Manchester University NHS Foundation Trust. North West Genomic Laboratory Hub. https://mft.nhs.uk/nwglh/ (accessed August 2023). 35. Birmingham Women's and Children's NHS Foundation Trust. West Midlands Regional Genetics Laboratory. https://bwc.nhs.uk/west-midlands-regional-
- genetics-laboratory (accessed August 2023).
- 36. NHS East Genomics. East Genomic Laboratory Hub. https://www.eastgenomics.nhs.uk/about-us/genomic-laboratory-hub/ (accessed August 2023). 37. NHS North Thames Genomic Laboratory Hub. North Thames Genomic Laboratory Hub for somatic cancer testing. https://www.norththamesglh.nhs.uk/north-
- west-thames-regional-genetics-service/ (accessed August 2023).
- 38. NHS South East Genomics. South East Genomics. https://southeastgenomics.nhs.uk/who-we-are/ (accessed August 2023).










LYNPARZA MoA^{8,12,13}

Normal cell:



Tumour cell with BRCA1 and/or BRCA2 mutation:





Figure adapted from Cerrato A, et al. J Exp Clin Cancer Res 2016.¹³



Tumour tissue testing



- Identifies germline and somatic mutations, but does not distinguish between them; blood germline testing can be used to confirm this¹⁶
- Fresh and archival tissue can be used¹⁷
- Primary or metastatic tumour tissue can be used¹⁷



ctDNA testing



- Identifies germline and somatic mutations, but does not distinguish between them; blood germline testing can be used to confirm this^{16,18,19}
- Clinical trials are exploring the use of ctDNA as a type of liquid biopsy in prostate cancer²⁰
- Outside of clinical trials there is currently limited use of ctDNA as a method of identifying mutations in prostate cancer²⁰
- If tumour tissue testing fails or is not feasible, if available, ctDNA testing could be used to identify patients with a BRCA mutation in mCRPC who may derive benefit from LYNPARZA monotherapy treatment²¹



Blood germline testing


- Identifies germline mutations, but not somatic mutations, from DNA present in a blood sample^{16,22}
- Confirms if the mutation is an inheritable germline mutation confering familial risk¹⁵



- The NHS Scotland genetics services are delivered through the Scottish Genetics Laboratory Consortium (SGLC). The SGLC comprises four regional genetics centres in Aberdeen, Dundee, Edinburgh and Glasgow²⁴⁻²⁶
- BRCA testing services currently being offered by the Glasgow and **Aberdeen** centres:
 - West of Scotland Genetics Service (Glasgow) https://www.nhsggc.scot/staff-recruitment/staff-resources/laboratorymedicine/laboratory-genetics/
 - North of Scotland Genetics Service (Aberdeen) https://www.nhsgrampian.org/service-hub/north-of-scotland-medicalgenetics/



- In Wales, there is one genomic testing NHS service that delivers BRCA testing:²⁷
 - All Wales Medical Genomics Service
 https://medicalgenomicswales.co.uk/



- In Northern Ireland, there is one genomic testing NHS service that delivers BRCA testing:²⁸
 - **Regional Genetics Service**

https://belfasttrust.hscni.net/service/laboratory-services/clinical-genetics/



- North East and Yorkshire³³
 - North East and Yorkshire Genomic Laboratory Hub https://www.leedsth.nhs.uk/a-z-of-services/the-leeds-genetics-laboratory/

• North West³⁴

North West Genomic Laboratory Hub <u>https://mft.nhs.uk/nwglh/</u>




Central and South³⁵

West Midlands Regional Genetics Laboratory https://bwc.nhs.uk/west-midlands-regional-genetics-laboratory







• East Genomic Laboratory Hub https://www.eastgenomics.nhs.uk/about-us/genomic-laboratory-hub/



• North Thames³⁷

North Thames Genomic Laboratory Hub https://www.norththamesglh.nhs.uk/



South East³⁸

South East Genomics https://southeastgenomics.nhs.uk/



• South West³²

South West Genomic Laboratory Hub https://www.nbt.nhs.uk/south-west-genomic-laboratory-hub

